Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 176

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 176
---
181 |     |            |   * |   |
| Chester S. Zygmont, III(7)                              |     |              | 15,090 |     |            | 1.6 | % |
| All Directors and Officers as a Group (Six Individuals) |     |              | 46,090 |     |            | 5.0 | % |

| * | Less than one percent. |

| (1) | Unless otherwise indicated, the business address of each                                                           
 of the individuals is c/o Revelation Biosciences, Inc., 4660 La Jolla Village Dr., Suite 100, San Diego, CA 92122. |

| (2) | Consists of (i) 42 shares of common stock held directly                                                                  
 by Mr. Rolke, (ii) 30,095 shares of common stock from the February 11, 2025 Restricted Stock Award (“RSA”)               
 grant to Mr. Rolke, (iii) 2 shares of common stock from Rollover RSU’s vesting and issuable within 60 days to Mr. Rolke, 
 and (iv) 3 shares of common stock underlying Stock Options exercisable within 60 days by Mr. Rolke.                      |

| (3) | Consists of (i) 87 shares of common stock held by George                                                                     
 Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust, (ii) 181 shares of common stock from the February 11, 2025 
 RSA grant to Dr. Tidmarsh, and (iii) 13 shares of common stock underlying Stock Options exercisable within 60 days by        
 Dr. Tidmarsh.                                                                                                                |

| (4) | Consists of (i) 6 shares of common stock held directly                                                                
 by Ms. Carver (ii) 181 shares of common stock from the February 11, 2025 RSA grant to Ms. Carver, and (iii) 13 shares 
 of common stock underlying Stock Options exercisable within 60 days by Ms. Carver.                                    |

| (5) | Consists of (i) 2 shares of common stock held directly                                                       
 by Mr. Roper (ii) 181 shares of common stock from the February 11, 2025 RSA grant to Mr. Roper, and (iii) 13 
 shares of common stock underlying Stock Options exercisable within 60 days by Mr